- ►diabetesjournals.org [PDF] P Raskin, L Jovanovic, S Berger, S Schwartz, … - Diabetes Care, 2000 - Am Diabetes Assoc From the University of Texas Southwest Medical Center (PR), Dallas, Texas; the
Sansum Medical Research Institute (LJ), La Jolla, California; the Chicago Center
for Clinical Research (SB), Chicago, Illinois; the Dia- betes and Glandular ... Cited by 43 - Related articles - BL Direct - All 5 versions
R Moses, R Slobodniuk, S Boyages, S Colagiuri … - Diabetes Care, 1999 - Am Diabetes Assoc I n the US, there are 7 million people with diagnosed type 2 diabetes (1).
Within the first 10 years of diagnosis, mo re than half of all those with type 2
dia- betes take oral hypoglycemic agents (2). ... Between 1970 and 1995, ... Cited by 215 - Related articles - BL Direct - All 7 versions
BHR Wolffenbuttel, R Landgraf - Diabetes Care, 1999 - Am Diabetes Assoc T ype 2 diabetes is a heterogeneous diso rder characterized by impaire d insulin
secretion, diminished periph- eral insulin action, and increased hepatic glucose
production (1,2). The major thera- peuticgoalsinthesepatients aretooptimize ... Cited by 87 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] DA de Luis, R Aller, L Cuellar, C Terroba, H … - Diabetes Care, 2001 - Am Diabetes Assoc Diabetes is a group of metabolic dis- eases characterized by hyperglyce- mia.
Clinical expression of diabetes is dependent on both genetic and ac- quired
factors (1). The metabolic effects of oxidants, which are believed to ... Cited by 13 - Related articles - BL Direct - All 4 versions
[CITATION] The efficacy of repaglinide administered in combination with bedtime NPH-insulin in patients …
- ►diabetesjournals.org [PDF] ES Horton, F Whitehouse, MN Ghazzi, TC … - Diabetes Care, 1998 - Am Diabetes Assoc Type 2 diabetes is a chronic and pro- g ressive disease that affects more than
16 million people in the US, half of whom do not even know they have the disease
(1,2). The cost of tre ating diabetes and its long-term complications ( re ... Cited by 99 - Related articles - BL Direct - All 5 versions
R Landgraf, HJG Bilo, PG Müller - European journal of clinical pharmacology, 1999 - Springer Abstract Objective: To compare the e cacy and safety of repaglinide, a novel
oral prandial glucose regulator, with that of glibenclamide, an oral
hypoglycaemic agent, in the treatment of patients with type 2 diabetes. ... Cited by 72 - Related articles - All 3 versions
M Buysschaert, E Bobbioni, M Starkie, L Frith - Diabetic Medicine, 1999 - ingentaconnect.com Results At week 16, adjusted geometric mean HbA1c with troglitazone 100 mg
(7.7%; P = 0.023) and 200 mg (7.4%; P < 0.001) was lower with sulphonylurea
alone (8.2%). At all weeks, adjusted geometric mean fasting serum glucose ... Cited by 20 - Related articles - BL Direct - All 3 versions
CB Juhl, N Porksen, M Hollingdal, J Sturis, S … - Diabetes care, 2000 - Am Diabetes Assoc I nsulin release is characterized by a coordi- nated pulsatile mode of secretion
with a periodicity of 5–15 min/pulse, leading to oscillations in peripheral
insulin concentra- tions (1,2). The impact of pulsatile insulin delivery on ... Cited by 19 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org [PDF] P Damsbo, P Clauson, TC Marbury, K … - Diabetes Care, 1999 - Am Diabetes Assoc Type 2 diabetes is caused by both impai red insulin secretion and dec reased
insulin sensitivity. Although the prevalence of type 2 diabetes varies between
diff e rent populations, the disease has been re po rted to affect more ... Cited by 113 - Related articles - BL Direct - All 5 versions
